Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFNα in patients with metastatic melanoma

The purpose of this study is to determine the toxicity and efficacy of temozolomide (TMZ) p.o. followed by subcutaneous (s.c.) low-dose interleukin-2 (IL2), granulocyte–monocyte colony stimulating factor (GM-CSF) and interferon-α 2b (IFNα) in patients with metastatic melanoma. A total of 74 evaluabl...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: de Gast, G C, Batchelor, D, Kersten, M J, Vyth-Dreese, F A, Sein, J, van de Kasteele, W F, Nooijen, W J, Nieweg, O E, Waal, M A de, Boogerd, W
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2003
Matèries:
Clinical
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2377058/
https://ncbi.nlm.nih.gov/pubmed/12610499
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6600717
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars